Patent Troll Legislation Would Alter PTO’s Validity Challenge Proceedings
This article was originally published in The Rose Sheet
Legislation under consideration in both U.S. congressional houses seeks to address abusive patent litigation practices. At a recent Senate Judiciary Committee hearing, the Biotechnology Industry Organization expressed support for a Senate bill’s proposed revisions, including changes to the PTO’s increasingly popular inter partes review process, while arguing against provisions in a related House measure.
You may also be interested in...
“One-size-fits-all” patent troll bill will harm innovators, Johnson & Johnson’s chief IP counsel tells Senate hearing.
Agency's final rule defines protein based on size of amino acid sequence, irrespective of method of manufacture, saying this 'bright-line rule' provides regulatory certainty.
Sanofi follows Janssen in teaming up with HHS' BARDA to develop a COVID-19 vaccine; using technology platform of its Flublok vaccine, Sanofi expects to enter clinical trials in 1 to 1 ½ years.